By Colin Kellaher Minerva Neurosciences shares lost more than half of their value in early trading Tuesday after the U.S. Food and Drug Administration once.
By Colin Kellaher The Food and Drug Administration has officially pulled its authorization of the anticancer drug Pepaxto from Swedish biotech Oncopeptides..
By Josh Beckerman Bright Green shares were recently up 43% to 27 cents Thursday after the company received final approval for "unique licensing" for certain.
By Colin Kellaher Regeneron Pharmaceuticals has won U.S. Food and Drug Administration priority review for its application seeking approval of linvoseltamab.
By Dean Seal Shares of Iovance hit a 52-week high after the company's $211 million underwritten offering was priced and it announced key approvals from.